Product Description
SLN124 is a double-stranded small interfering ribonucleic acid (siRNA) targeting transmembrane protease, serine 6 (TMPRSS6) messenger ribonucleic acid (mRNA). (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05499013)
Mechanisms of Action: TMPRSS6 Inhibitor
Novel Mechanism: Yes
Modality: Nucleic Acid
Route of Administration: Subcutaneous
FDA Designation: Fast Track - Polycythemia|Polycythemia Vera *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Silence
Company Location: LONDON X0 W14 8TH
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Bulgaria, Germany, Israel, Italy, Jordan, Malaysia, Poland, Spain, Thailand, United Kingdom, United States
Active Clinical Trial Count: 3
Highest Development Phases
Phase 2: Polycythemia Vera
Phase 1: Myelodysplastic Syndrome|Preleukemia|beta-Thalassemia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| SLN124-004 | P2 |
Unknown Status |
Polycythemia Vera |
2029-06-04 |
|
| SLN | P2 |
Recruiting |
Polycythemia Vera |
2024-12-01 |
57% |
| SLN124-002 | P1 |
Completed |
Preleukemia|beta-Thalassemia|Myelodysplastic Syndrome |
2023-05-23 |
21% |